Requiring Department of Health to report positive alpha-gal tests to CDC
Summary
SB773 would amend West Virginia’s public health rulemaking statute to direct the Secretary of the Department of Health to propose legislative rules adding alpha-gal syndrome to the list of diseases that must be reported to the Centers for Disease Control and Prevention. The bill’s stated purpose is to ensure positive alpha-gal tests are reported, which would place the condition within the state’s communicable-disease reporting framework and support public health surveillance.
The bill does not create a new standalone disease-control program, but it does require the Department of Health to take rulemaking action under existing authority in §16-1-4. In practical terms, it would affect the state’s disease reporting obligations, public health data collection, and any providers or laboratories subject to mandatory reporting rules once those rules are adopted. The bill also leaves intact the broader public health rulemaking provisions already in the statute, which cover a wide range of health and sanitation topics.
Impact
SB773 would modify §16-1-4 of the West Virginia Code by adding alpha-gal syndrome to the list of conditions the Secretary must address through legislative rules for mandatory reporting to the CDC. The immediate legal effect is to require rulemaking rather than directly imposing a new reporting requirement in statute, but it would likely lead to updated reporting obligations for health care providers, laboratories, and public health officials once the rules are promulgated. It also expands the state’s surveillance of tick-related and allergy-related illness data within the public health system.
Sentiment
The available voting history suggests strong support for the bill: it passed the Senate unanimously, 26-0. No committee transcript was provided, so there is no recorded debate to indicate opposition or concern in the materials supplied. Overall, the bill appears to have been viewed as a straightforward public health measure with broad bipartisan or noncontroversial support.
Contention
No specific points of contention are documented in the provided materials. Because the bill requires the Department of Health to propose rules rather than directly mandating a detailed reporting regime, any potential concerns would likely center on implementation details, reporting burdens on providers and laboratories, or how alpha-gal syndrome is defined and tracked. However, the unanimous Senate vote indicates that no significant disagreement was reflected in the recorded action.